CA3219083A1 - Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor - Google Patents
Methods for treating or preventing influenza virus infection by administering a serine protease inhibitorInfo
- Publication number
- CA3219083A1 CA3219083A1 CA3219083A CA3219083A CA3219083A1 CA 3219083 A1 CA3219083 A1 CA 3219083A1 CA 3219083 A CA3219083 A CA 3219083A CA 3219083 A CA3219083 A CA 3219083A CA 3219083 A1 CA3219083 A1 CA 3219083A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- inhibitor
- tmprss2
- influenza
- ttsp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624519P | 2012-04-16 | 2012-04-16 | |
| US61/624,519 | 2012-04-16 | ||
| US201361759469P | 2013-02-01 | 2013-02-01 | |
| US61/759,469 | 2013-02-01 | ||
| CA2869010A CA2869010A1 (en) | 2012-04-16 | 2013-04-15 | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2869010A Division CA2869010A1 (en) | 2012-04-16 | 2013-04-15 | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219083A1 true CA3219083A1 (en) | 2013-10-24 |
Family
ID=48184523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219083A Pending CA3219083A1 (en) | 2012-04-16 | 2013-04-15 | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
| CA2869010A Withdrawn CA2869010A1 (en) | 2012-04-16 | 2013-04-15 | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2869010A Withdrawn CA2869010A1 (en) | 2012-04-16 | 2013-04-15 | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9498529B2 (https=) |
| EP (2) | EP3536342A1 (https=) |
| JP (2) | JP6446355B2 (https=) |
| KR (1) | KR20150008383A (https=) |
| CN (1) | CN104244978A (https=) |
| AU (2) | AU2013249577A1 (https=) |
| BR (1) | BR112014025339A8 (https=) |
| CA (2) | CA3219083A1 (https=) |
| HK (1) | HK1202817A1 (https=) |
| MX (1) | MX2014012285A (https=) |
| NZ (1) | NZ631105A (https=) |
| SG (1) | SG11201405163RA (https=) |
| WO (1) | WO2013158516A1 (https=) |
| ZA (1) | ZA201406194B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| KR101693243B1 (ko) * | 2016-06-15 | 2017-01-05 | 재단법인 한국파스퇴르연구소 | 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도 |
| LT3638698T (lt) * | 2018-01-26 | 2021-04-12 | Regeneron Pharmaceuticals, Inc. | Antikūnai prieš tmprss2 ir antigeną surišantys fragmentai |
| MX2022009476A (es) | 2020-02-10 | 2022-08-22 | Regeneron Pharma | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. |
| WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
| WO2021195119A1 (en) * | 2020-03-24 | 2021-09-30 | Corcept Therapeutics Incorporated | Methods of reducing the risk of, severity of, and treating coronavirus infections |
| EP3964207A1 (en) | 2020-09-02 | 2022-03-09 | Christian-Albrechts-Universität zu Kiel | Antiviral pharmaceutical composition for topical administration |
| WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4839999A (en) * | 1998-06-29 | 2000-01-17 | Myriad Genetics, Inc. | Tmprss2 is a tumor suppressor |
| WO2004097358A2 (en) | 2003-05-02 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2) |
| JP5366406B2 (ja) * | 2005-01-07 | 2013-12-11 | レキシコン ファーマシューティカルズ インコーポレーテッド | アンジオポエチン様タンパク質４（ａｎｇｐｔｌ４）に対するモノクローナル抗体 |
| WO2007089903A2 (en) | 2006-02-01 | 2007-08-09 | Brigham Young University | Cationic steroid microbial compositions for treating or preventing influenza infections |
| JP2008247864A (ja) * | 2007-03-30 | 2008-10-16 | Univ Of Tokushima | モザイクセリンプロテアーゼ、ｍｓｐとその用途 |
| JP2008308438A (ja) * | 2007-06-14 | 2008-12-25 | Mitsubishi Tanabe Pharma Corp | 新規なインフルエンザ治療および／または予防薬 |
| BRPI1014745B1 (pt) | 2009-06-22 | 2020-10-20 | Borealis Ag | artigo para interior de automóveis com odor reduzido |
| DK3702374T3 (da) * | 2012-02-15 | 2022-06-27 | Cydex Pharmaceuticals Inc | Fremsgangsmåde til fremstilling for cyclodextrin-derivater |
-
2013
- 2013-04-15 HK HK15103529.7A patent/HK1202817A1/xx unknown
- 2013-04-15 CA CA3219083A patent/CA3219083A1/en active Pending
- 2013-04-15 BR BR112014025339A patent/BR112014025339A8/pt not_active Application Discontinuation
- 2013-04-15 EP EP19155349.4A patent/EP3536342A1/en not_active Withdrawn
- 2013-04-15 AU AU2013249577A patent/AU2013249577A1/en not_active Abandoned
- 2013-04-15 CN CN201380020133.9A patent/CN104244978A/zh active Pending
- 2013-04-15 SG SG11201405163RA patent/SG11201405163RA/en unknown
- 2013-04-15 WO PCT/US2013/036522 patent/WO2013158516A1/en not_active Ceased
- 2013-04-15 KR KR1020147028956A patent/KR20150008383A/ko not_active Ceased
- 2013-04-15 MX MX2014012285A patent/MX2014012285A/es active IP Right Grant
- 2013-04-15 CA CA2869010A patent/CA2869010A1/en not_active Withdrawn
- 2013-04-15 JP JP2015507076A patent/JP6446355B2/ja active Active
- 2013-04-15 US US13/862,497 patent/US9498529B2/en active Active
- 2013-04-15 NZ NZ631105A patent/NZ631105A/en unknown
- 2013-04-15 EP EP13718744.9A patent/EP2838558A1/en not_active Ceased
-
2014
- 2014-08-22 ZA ZA2014/06194A patent/ZA201406194B/en unknown
-
2017
- 2017-10-20 JP JP2017203146A patent/JP2018048169A/ja not_active Withdrawn
-
2018
- 2018-01-12 AU AU2018200265A patent/AU2018200265B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013158516A1 (en) | 2013-10-24 |
| JP2018048169A (ja) | 2018-03-29 |
| AU2018200265A1 (en) | 2018-02-01 |
| HK1202817A1 (en) | 2015-10-09 |
| NZ631105A (en) | 2016-09-30 |
| EP3536342A1 (en) | 2019-09-11 |
| JP6446355B2 (ja) | 2018-12-26 |
| BR112014025339A8 (pt) | 2018-01-16 |
| JP2015516975A (ja) | 2015-06-18 |
| ZA201406194B (en) | 2016-08-31 |
| US20130273070A1 (en) | 2013-10-17 |
| MX2014012285A (es) | 2015-04-13 |
| US9498529B2 (en) | 2016-11-22 |
| CN104244978A (zh) | 2014-12-24 |
| AU2013249577A1 (en) | 2014-10-02 |
| AU2018200265B2 (en) | 2019-07-18 |
| BR112014025339A2 (pt) | 2013-10-24 |
| CA2869010A1 (en) | 2013-10-24 |
| KR20150008383A (ko) | 2015-01-22 |
| EP2838558A1 (en) | 2015-02-25 |
| SG11201405163RA (en) | 2014-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018200265B2 (en) | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor | |
| US11167004B2 (en) | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor | |
| KR102462039B1 (ko) | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 | |
| AU2017332732B2 (en) | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor | |
| US20230102151A1 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| TW202432598A (zh) | 藉由投予il-4r拮抗劑治療手足皮膚炎的方法 | |
| HK40014386A (en) | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor | |
| RU2845158C1 (ru) | Способы лечения атопического дерматита путем введения антагониста il-4r | |
| HK40103467A (en) | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor | |
| KR20240046243A (ko) | 항-il-13 항체 제제 | |
| HK40010552A (en) | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor | |
| HK40010552B (en) | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240126 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250912 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20251230 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260105 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260105 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260319 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260319 |